Medicare paid patients the lower of either 80 percent of theurologist’s charge for Lupron or the average wholesale price of the drug (as set byTAP). Lupron is similar—in terms of its availability and efficacy—to a competingand significantly less expensive prostate cancer drug, Zoladex. Yet...